ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Sleep Apnea Solution Achieves 92% Satisfaction Without CPAP: Back2Sleep Announces Clinical Results

-- In a breakthrough for millions seeking a sleep apnea solution without CPAP, Back2Sleep, a European medical device company, announces a 92% user satisfaction rate for its innovative nasal stent. The CE-certified device offers a non-invasive, travel-friendly alternative to bulky CPAP machines and jaw-repositioning devices.

With over 1 million units distributed globally and availability through 57,000 pharmacies, Back2Sleep is quickly becoming the go-to choice for those who want better sleep without compromising comfort or mobility.

Addressing a Global Sleep Health Challenge

An estimated 22 million Americans and 175 million Europeans suffer from sleep apnea, with 80% remaining undiagnosed. For many, traditional CPAP machines present barriers including discomfort, high cost, and dependency on electricity.

Back2Sleep's nasal stent provides a simpler path. Designed to maintain nasal airway patency, the soft silicone stent is inserted in just 10 seconds and silently works throughout the night—no straps, no masks, and no noise.

Clinical-Backed User Satisfaction

Key user-reported results:

  • 92% satisfaction rate among surveyed users

  • Noticeable sleep comfort improvement within the first week

  • High retention and repeat use compared to CPAP and MADs

  • Portable, discreet, and easy to use

  • Skin-tested, medical-grade materials with multiple sizing options

According to a 2024 peer-reviewed clinical trial published in the European Respiratory Journal, Back2Sleep demonstrated a 64% reduction in AHI (apnea-hypopnea index) and 96%+ oxygen saturation maintenance over six months of use.

Innovation Born from ENT Expertise

Backed by 10 years of research and development under the guidance of ENT specialist Prof. Frédéric Chabolle, the device is engineered for people who cannot tolerate CPAP or are looking for a pre-surgical alternative.

“Back2Sleep offers a direct, comfortable solution to airway obstruction during sleep,” said Professor Chabolle. “It’s discreet, effective, and widely appreciated by patients.”

Business & Market Highlights

  • 1+ million tubes sold across Europe, North America, and Asia

  • Partnerships with 57,000+ pharmacies

  • Competitive pricing: Starter Kit from €39, monthly cost from €0.83/night

  • Subscription and size options available

As global demand grows for simple, effective, and portable sleep solutions, Back2Sleep positions itself as a leader in sleep comfort innovation.

About Back2Sleep

Back2Sleep is a European medical device company focused on innovative treatments for snoring and sleep apnea. Its CE-certified nasal stent is the result of a decade of clinical research and ENT expertise. The device is not intended to diagnose or treat sleep disorders. Users should consult a healthcare professional if sleep apnea is suspected.

Contact Info:
Name: Back2Sleep
Email: Send Email
Organization: Back2Sleep
Website: https://back2sleep.eu/

Release ID: 89169431

If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.